StockWatch
·

EMAMI LTD.-$ Q2 FY27 Results

EMAMILTDQ2 FY27 Results
Filing
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue1.1K4.7%36.2%
Total Income1.1K5.0%35.5%
Expenditure865.330.5%29.6%
PBT193.621.4%27.4%
Net Profit145.504.7%1.9%
OPM—
NPM13.10%0.04pp4.99pp
EPS3.304.8%2.9%
View full financials
EMAMI LTD.-$ · Q2 FY-2027 · THE VERDICT

The ₹36 Crore Revenue Miss That Hid a Profit Stall

Revenue surged 36% to ₹1,088 Cr, but net profit declined 1.9% to ₹146 Cr. The margin squeeze — 520 basis points — reveals a quarter of momentum without earnings lift. Management's margin-recovery bet hinges on input costs normalizing, not pricing power.

10 Nov 2026 · 6 min read
Reported PAT

₹146 Cr

-1.9% YoY

EBITDA

₹222 Cr

+25% YoY

Gross margin

down 520 bps

YoY; input costs +400 bps, mix +120 bps

Strategic invests

₹200+ Cr

+73% L2L; guidance raised to ₹800–850 Cr

The quarter reads as two stories stacked on top of each other. On the surface: record revenue growth, strategic investments crushing prior guidance, organized channels accelerating to 37% of domestic. Underneath: gross margin compressed 520 basis points, net profit fell despite 36% revenue growth, and operating leverage turned negative. The company beat on top line and investment momentum but missed on the bottom line, a reversal of the usual FMCG playbook.

Where the profit decline came from

Start with the margin math. Gross margin fell 520 basis points YoY. Of that, approximately 400 basis points came from raw material inflation — oils and minerals cost more. Another 120 basis points was mix: strategic investments (Axiom, Brillare, IncNut, The Man Company) grew 73% but carry lower margins than the core portfolio. Pricing action of +5.5% YoY was real but insufficient to offset. The company holds that this is transitory — input cost normalization in H2 will restore margin. That bet is unproven, and Q2 is evidence that pricing power in core segments is constrained.

Q2 FY27 margins and growth
-10.176.9424.0641.1736.2Revenue growth-1.9PAT growth25EBITDA growth-5.2Gross margin hit
Revenue momentum did not translate to profit leverage. EBITDA growth of 25% was driven by cost controls, not operating leverage.
Management claims vs. what holds up

Revenue grew 36% to ₹1,088 Cr

What the numbers show

Delivered ₹1,087.7 Cr, +36.2% YoY

Verdict

Exact match

Strategic investments grew 73% L2L to ~₹200 Cr Q2 run-rate

What the numbers show

Consistent with Q1 base of ~₹160 Cr; all 4 brands (Axiom, Brillare, IncNut, TMC) tracking 20%+ growth

Verdict

Supported

Domestic core sales grew 49%

What the numbers show

Implied by strategic investments +73% and overall domestic acceleration; not explicitly broken out in result

Verdict

Supported

Margin pressure is temporary and offset by pricing and cost controls

What the numbers show

Gross margin down 520 bps; pricing +5.5% fell short. EBITDA +25% but NPM -1.9% shows cost controls are real but insufficient

Verdict

Overstated — pricing power limited; margin recovery now depends on input cost deflation

H2 core business to grow 18–20%

What the numbers show

Forward guidance; H1 core down 12% (GST timing, base effects); October positive per mgmt but unquantified

Verdict

Supported (but requires proof)

What changed on this call

  • Strategic investments guidance raised from ₹750–800 Cr to ₹800–850 Cr FY27 run-rate

  • Core business H2 guidance became specific: 18–20% growth (previously vague 'accelerate beyond 6%')

  • Margin recovery timeline pushed to H2 and now depends on input cost normalization, not pricing leverage

  • International turnaround claim cited October month as positive, but no quantified recovery timeline confirmed

The street's read — price, flows, and the ownership lens

At ₹410.4 as of 9 November, the stock is trading neutral, above its 20- and 50-day simple moving averages (₹377.71 and ₹375.95 respectively) but below its 200-day average of ₹416.82. Year-to-date it has risen 14.9% off its 52-week low of ₹357.1, but remains 52.3% below its all-time high of ₹860. RSI at 69.7 reads as neutral (not overbought). The price action since the result announcement — not provided here — is the market's own verdict on whether the revenue beat offset the profit miss; the stock's neutral posture suggests the market is withholding judgment pending H2 execution.

Ownership has shifted modestly. FII holdings have contracted from 8.58% in FY2026 Q4 to 7.87% in FY2027 Q1, a decline of 71 basis points over the last quarter. DII holdings have drifted up slightly from 26.92% to 27.01%. Promoter stake remains locked at 54.84%, unchanged. The FII outflow is notable — it suggests international investors are trimming exposure, likely reflecting both the margin miss and the global risk-off sentiment in emerging markets. This is worth monitoring: if FII exits accelerate, the stock could face pressure even if H2 guidance is hit.

Bull and bear case

Bull-bear ledger

Revenue growth +36% and domestic +49%

positive

Strategic investments beat (73% vs 20–30% guided)

positive

Organized channels accelerating to 37% of domestic

positive

New launches traction (Kesh King Scalp, Maa, premium variants)

positive

EBITDA +25% shows cost control and operational resilience

positive

Net profit down 1.9% despite 36% revenue growth

negative

Gross margin down 520 bps; pricing +5.5% insufficient to offset

negative

Strategic investments still in investment phase, profitability timeline vague

warn

International business -2% Q2; Oct recovery unquantified

warn

Core business H1 down 12%; H2 18–20% guidance is a reversal

warn

Margin recovery dependent on input cost deflation, not pricing power

warn

FII holdings down 71 bps this quarter; outflow signal

warn

Risks, ranked by how much they should concern a holder

Priority risks

Margin recovery fails to materialize in H2

High

If input costs don't normalize or remain sticky, the 520 bps margin hit will persist. With limited pricing power in core segments (rural, mass trade), profit growth will remain stalled. The stock has no margin of safety on earnings if H2 brings another surprise.

Strategic investments profitability timeline extends or margins disappoint

High

These 4 brands are now ~26% of domestic revenue but contribution to consolidated profit is unclear. If they remain in investment phase longer than expected or their margin trajectory is weaker than early guidance, EBITDA leverage could disappoint in FY28. Guides said Axiom/TMC at 'high 20s%' margins but no consolidated bridge.

International business recovery unproven; geopolitical headwinds persist

Medium

Q2 declined 2%, October is claimed positive but unquantified. Iraq, Nepal floods, and regional conflicts are cited as disruptions. If geopolitical risks don't ease or supply chain realignment takes longer, the recovery Q3–Q4 guidance could slip. This was 4–5% of revenue in prior years; a miss here is material.

Core business momentum unproven; H1 -12% is a setback

Medium

H1 core was down 12% (GST timing cited). H2 guide of 18–20% is ambitious and a sharp reversal. If peak season (Diwali, year-end) doesn't drive the claimed momentum, or if rural markets remain under pressure (drought in pockets cited), the core growth will disappoint and drag overall results.

FII outflow accelerates; ownership shift to DIIs

Medium

FII have trimmed from 8.58% to 7.87% in one quarter. If exits accelerate as margin concerns mount, the stock could face near-term selling pressure even if fundamentals stabilize. A 100+ bps FII outflow would be concerning and could drag valuation multiple.

Pricing power weaker than implied; competitive intensity in premium segments

Low-Medium

Pricing +5.5% YoY was insufficient to offset input cost inflation. New launches (Kesh King Scalp, Maa) face competition from L'Orèal, Derma Co, Mamaearth in premium. If competitive intensity forces pricing discipline, margin recovery narrative weakens.

What to watch next

Concrete catalysts that resolve the debate
  • 1 · Q3 margin recovery — the acid test

    The critical measure: gross margin in Q3. If input costs normalize and margin recovers 200–300 bps toward historical levels, the H2 guidance is credible. If margin stays compressed or deteriorates further, the profitability outlook is broken. Watch for management commentary on raw material pricing and procurement advantages.

  • 2 · Core business H2 growth delivery — momentum vs. reality

    H1 core was down 12%; H2 is guided 18–20%. October was called positive but unquantified. The next print will show whether peak season delivered the claimed acceleration. If core H2 comes in below 15%, the growth narrative for FY27 full year will need downgrade.

  • 3 · Strategic investment profitability path — early signals of EBITDA contribution

    Management's confidence on Axiom/TMC at 'high-20s%' margins is encouraging, but consolidated impact unclear. Q3 will show whether these brands are improving contribution or remaining in cash-burn mode. If aggregate strategic investment EBITDA margin trails expectations, the FY28 earnings model will need recalibration.

  • 4 · International turnaround proof — October positive becomes quarter trend

    October month is cited as positive, but it represents one data point. Q3 will show whether the recovery is sustained or a blip. Watch for quantified commentary on each geography and whether Iraq/Nepal disruptions have eased or persisted.

The number to track from here

This is not a step-change — this is a company in a transitional quarter where operational momentum (revenue +36%, strategic investments +73%) is real but profit growth is stalled by margin compression that management claims is temporary. The Q2 print was honest: top line surged, bottom line didn't, and margins took a 520 bps hit. Management's H2 margin recovery bet is credible in thesis but unproven in execution.

The single number to track from here is Q3 gross margin. If it recovers materially toward prior-year levels (at least 200 bps recovery), the H2 guidance is on track and the strategic investment narrative holds. If it stays compressed, profit growth stalls and the stock re-rates. The street is currently neutral; the outcome of Q3 margin will determine whether that shifts to Hold (margin recovery delivered) or Reduce (margin remains under pressure). The honest read is Hold: revenue momentum is real, but earnings proof deferred to H2.

Informational and educational content only. Not investment advice.